INmune Bio Inc (INMB) Chairman Buys $109,890.00 in Stock
INmune Bio Inc (NASDAQ:INMB) Chairman Raymond Joseph Tesi acquired 11,100 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was purchased at an average price of $9.90 per share, with a total value of $109,890.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of INMB stock opened at $10.50 on Tuesday. INmune Bio Inc has a 12 month low of $7.00 and a 12 month high of $11.25.
Separately, Maxim Group started coverage on INmune Bio in a research report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price objective for the company.
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
See Also: Diversification For Individual Investors
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.